PRODUCT CODE: EM1901-38

F13A1 Monoclonal Antibody (EM1901-38)

Applications

  • WB

  • IHC-P

  • FC

REACTIVITY

  • Human

Western blot analysis of F13A1 on human placenta tissue lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (EM1901-38, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.
  • Western blot analysis of F13A1 on human placenta tissue lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (EM1901-38, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.
  • Immunohistochemical analysis of paraffin-embedded human placenta tissue using anti-F13A1 antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 8.0-8.4) for 20 minutes.The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (EM1901-38, 1/800) for 30 minutes at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Flow cytometric analysis of F13A1 was done on A549 cells. The cells were fixed, permeabilized and stained with the primary antibody (EM1901-38, 1/50) (red). After incubation of the primary antibody at room temperature for an hour, the cells were stained with a Alexa Fluor 488-conjugated Goat anti-Mouse IgG Secondary antibody at 1/1000 dilution for 30 minutes.Unlabelled sample was used as a control (cells without incubation with primary antibody; black).
Western blot analysis of F13A1 on human placenta tissue lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (EM1901-38, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.

Applications

  • WB

  • IHC-P

  • FC

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Mouse monoclonal primary

Product Name

F13A1 Monoclonal Antibody (EM1901-38)

Immunogen

Recombinant protein within human f13a1 aa 250-500.

Host

Mouse

Positive Control

Human placenta tissue lysates, human placenta tissue, A549.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

16D3

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

2 ug/ul

PURIFICATION

Protein A affinity purified.

MOLECULAR WEIGHT

83 kDa

Isotype

IgG1

APPLICATION DILUTION

  • WB:1:500-1:2,000

  • IHC-P:1:200-1:1,000

  • FC:1:50-1:100

TARGET

UNIPROT #

PROTEIN NAME

F13A1

SYNONYMS

bA525O21.1 (coagulation factor XIII, A1 polypeptide) antibody; Coagulation factor XIII A chain antibody; Coagulation factor XIII A1 polypeptide antibody; Coagulation factor XIII A1 subunit antibody; Coagulation factor XIII, A polypeptide antibody; Coagulation factor XIIIa antibody; F13A antibody; F13A_HUMAN antibody; F13a1 antibody; Factor XIIIA antibody; Fibrin stabilizing factor, A subunit antibody; Fibrinoligase antibody; FSF, A subunit antibody; Protein glutamine gamma glutamyltransferase A chain antibody; Protein-glutamine gamma-glutamyltransferase A chain antibody; TGase antibody; Transglutaminase A chain antibody; Transglutaminase, plasma antibody; Transglutaminase. plasma antibody

SEQUENCE SIMILARITIES

Belongs to the transglutaminase superfamily. Transglutaminase family.

POST-TRANSLATIONAL MODIFICATION

The activation peptide is released by thrombin.

SUBCELLULAR LOCATION

Secreted, cytoplasm.

FUNCTION

Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin, and factors V, VIII, IX and X), which are involved in a blood coagulation cascade leading to the formation of insoluble fibrin clots and the promotion of platelet aggregation. Coagulation factor VII (serum prothrombin conversion accelerator, proconvertin, F7, Factor VII) is a 406 amino acid, vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor. Factor IXa, factor Xa, factor XIIa, or thrombin mediated proteolytic cleavage of Factor VII at Arg152-Ile153 generates Factor VIIa, an active serine protease composed of a catalytic heavy chain disulfide linked to a light chain, containing two EGF-like domains. Coagulation factor XIII is a terminal effector in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of two A subunits and two B subunits. The A subunits have catalytic function, and the noncatalytic B subunits may serve as plasma carrier molecules.